Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from ...

Shares of Fulcrum Therapeutics (NASDAQ:FULC) rose on Friday after Leerink Partners upgraded the Cambridge, Massachusetts-based biopharma, citing a favorable risk-reward setup ahead of a trial readout ...

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Leerink Partners on Friday upgraded Fulcrum Therapeutics, Inc. (NASDAQ:FULC) to Outperform from Market Perform, and raised the stock’s price target to $12 per share from $4. The analyst cited a ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a “positive readthrough” from the J&J’s (JNJ) in-licensing of an oral ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to an acquisition by Transcarent. The firm views the ...

Leerink lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for ...

Leerink Partners, an advisory firm specializing in health-care deals, has hired two investment bankers from Evercore Inc. Bernhard Sakmann and Justin Reed will be joining Leerink and will be based ...

Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from Market Perform to Outperform. As of May 7, 2025, the average one-year ...